Neuphoria Therapeutics Inc. Restructuring Charges
Neuphoria Therapeutics Inc. (NEUP) reported Restructuring Charges of $42.41 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-05-15
- Neuphoria Therapeutics Inc. restructuring charges for the quarter ending 2026-03-31 was $42.41K.
- Neuphoria Therapeutics Inc. restructuring charges for the quarter ending 2025-12-31 was $1.24M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month |
|---|---|---|---|
| 2026-03-31 | $42.41K 10-Q · filed 2026-05-15 | $1.28M derived: sum of 2 quarters · filed 2026-05-15 | $1.28M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $1.24M 10-Q · filed 2026-02-17 | $1.24M 10-Q · filed 2026-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |